PD-1 Immunotherapy Erases Some Colorectal Tumors Without Surgery in dMMR Patients
Updated
Updated · Newsweek · Jun 5
PD-1 Immunotherapy Erases Some Colorectal Tumors Without Surgery in dMMR Patients
2 articles · Updated · Newsweek · Jun 5
Summary
Memorial Sloan Kettering-backed studies found PD-1 blockade produced complete clinical remission in some patients with locally advanced rectal cancer, eliminating tumors without chemotherapy, radiation or surgery.
The responses were seen in colorectal cancers with deficient mismatch repair or high microsatellite instability, a genetically defined subset that appears especially vulnerable to immune-based treatment.
Avoiding surgery could spare selected patients colostomies, long-term bowel dysfunction and other major complications if larger trials confirm the early results.
The finding lands as colorectal cancer rises among younger adults and precision medicine broadens treatment options, while screening from about age 45 remains the main tool to prevent disease and catch it early.
Could a simple genetic test soon make surgery for common cancers a thing of the past?
As immunotherapy replaces the scalpel, what are the hidden long-term risks of this revolutionary cancer treatment?
Why does this 'miracle' immunotherapy fail in many patients who seem to be perfect candidates for it?
Immunotherapy’s Dramatic Impact on dMMR Colorectal Cancer: Clinical Outcomes, Personalized Monitoring, and Future Challenges
Overview
Immunotherapy is dramatically changing the treatment of deficient DNA mismatch repair (dMMR) colorectal cancer by harnessing the body’s immune system to recognize and attack cancer cells. This approach is leading to less invasive and highly effective outcomes, offering significant hope for patients who previously faced surgery, radiation, or chemotherapy. Clinical trials, such as those at Memorial Sloan Kettering Cancer Center, have shown remarkable success, with patients treated using immunotherapy targeting tumors with specific genetic mutations. As a result, standard treatment protocols are being reshaped, marking a new era in care for dMMR colorectal cancer.